



King's Research Portal

DOI:

[10.1038/s41366-018-0095-0](https://doi.org/10.1038/s41366-018-0095-0)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Pataia, V., Papacleovoulou, G., Nikolova, V., Samuelsson, A-M., Chambers, S., Jansen, E., ... Williamson, C. (2018). Paternal cholestasis exacerbates obesity-associated hypertension in male offspring but is prevented by paternal ursodeoxycholic acid treatment. *International Journal of Obesity*. <https://doi.org/10.1038/s41366-018-0095-0>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

1 **Paternal cholestasis exacerbates obesity-associated hypertension in male offspring but is**
2 **prevented by paternal ursodeoxycholic acid treatment**

3

4 **Short title:** Impact of paternal cholestasis on progeny

5

6 Vanessa Pataia¹, Georgia Papacleovoulou¹, Vanya Nikolova¹, Anne-Maj Samuelsson¹,
7 Stephanie Chambers², Eugene Jansen³, Paul D Taylor¹, Lucilla Poston¹, Catherine
8 Williamson^{1*}

9

10 ¹Department of Women and Children's Health, King's College London, London, SE1 7EH,
11 United Kingdom.

12 ²Institute of Reproductive and Developmental Biology, Imperial College London, London
13 W12 0NN, United Kingdom

14 ³Centre for Health Protection, National Institute for Public Health and the Environment, PO
15 Box 1, 3720 BA, Bilthoven, Netherlands

16

17 ***Corresponding author:** Professor Catherine Williamson; Email address:
18 catherine.williamson@kcl.ac.uk; Telephone number: +44 20 7848 6350; Address: 2.30W
19 Hodgkin Building, King's College London, Guy's Campus, London, SE1 1UL, United
20 Kingdom.

21

22 **Conflict of interest:**

23 The authors have no conflict of interest to disclose.

24

25 **Financial support:**

26 The research was funded/supported by the Wellcome Trust (P30874), the Guy's and St
27 Thomas' Charity and by the National Institute for Health Research (NIHR) Biomedical
28 Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College
29 London. The views expressed are those of the author(s) and not necessarily those of the NHS,
30 the NIHR or the Department of Health.

31

32 **List of abbreviations**

33 Abcg5/8, ATP-binding cassette sub-family G member 5/8; Acc1/2, Acetyl-CoA carboxylase
34 1/2; ALT, alanine aminotransaminase; AUC, area under the curve; BAT, brown adipose tissue;
35 Bsep, bile salt export pump; CA, cholic acid; Cyp7a1, cholesterol 7-alpha-monooxygenase;
36 Cyp8b1, sterol 12-alpha-hydroxylase; FFAs, free fatty acids; Fas, fatty acid synthase; FXR,
37 farnesoid x receptor; GTT, glucose tolerance test; gWAT, gonadal white adipose tissue;
38 Hmgcr, HMG-CoA reductase; NC, normal-chow; NCDs, non-communicable diseases; Scd1,
39 stearyl-CoA desaturase 1; Shp, small heterodimer partner; Srebp-1c, sterol regulatory
40 element-binding protein 1c; sWAT, subcutaneous white adipose tissue; UDCA,
41 ursodeoxycholic acid; WD, western diet

42

43

44

45 **Abstract**

46 **Background:** Obesity is a heterogeneous phenotype and risk associations to non-
47 communicable diseases such as cardiovascular disease and type 2 diabetes are influenced by
48 several factors. The paternal metabolic status at the time of conception influences offspring
49 susceptibility to developing obesity and adiposity-associated cardiometabolic disease.
50 Cholestatic liver diseases are characterized by raised circulating serum bile acid levels and
51 dyslipidemia, and are commonly treated with ursodeoxycholic acid (UDCA). We hypothesized
52 that paternal cholestasis alters offspring susceptibility to developing obesity and adiposity-
53 associated cardiometabolic disease and that this may be modified by paternal UDCA treatment.

54 **Methods:** Cholestasis was induced in male C57BL/6 mice with a 0.5% cholic acid (CA)-
55 supplemented diet for 10 weeks prior to mating with normal chow (NC)-fed females. Offspring
56 of cholestatic and NC-fed fathers were fed either a NC diet or challenged with an obesogenic
57 ‘western diet’ (WD) from 12 weeks-old. Offspring body weight and cardiometabolic function
58 were assessed, and the impact of treatment of paternal cholestasis with UDCA was evaluated.

59 **Results:** Male offspring (18 weeks-old) of cholestatic fathers challenged with WD had raised
60 fasting insulin, hepatic triglyceride content and serum cholesterol levels compared to diet-
61 matched controls. At 25-29 weeks-old WD-fed male offspring of cholestatic fathers had higher
62 systolic and diastolic blood pressure than controls and this was prevented by paternal UDCA
63 treatment. In contrast, WD-challenged female offspring of cholestatic fathers showed improved
64 glucose tolerance compared to controls.

65 **Conclusions:** We demonstrated in our model of paternal cholestasis that offspring
66 susceptibility to adiposity-associated cardiometabolic disease is affected in a sex-specific
67 manner and paternal UDCA treatment had a protective effect against hypertension in the obese
68 male offspring. The most prevalent human cholestatic conditions are primary sclerosing

69 cholangitis and primary biliary cholangitis. These findings are of clinical relevance to children

70 of men with these conditions.

71

72 **Introduction**

73 Currently there is a world-wide epidemic of non-communicable diseases (NCDs) such as
74 cardiovascular disease and type 2 diabetes. Obesity is one of the main risk factors for
75 cardiovascular disease and type 2 diabetes¹. However, there is not a linear relationship between
76 body mass and NCDs and additional factors may influence individual disease risk².

77

78 Accumulating evidence suggests that not only maternal health, but also the paternal metabolic
79 status at the time of conception can impact the subsequent health of the offspring³. For example,
80 paternal obesity has been associated with long-term alterations in body fat percentage of
81 prepubertal daughters⁴ and early-onset paternal obesity is associated with raised alanine
82 aminotransaminase (ALT) in the offspring⁵. Food availability of grandfathers also impacts
83 upon longevity and cardiovascular risk in the progeny, as reported in studies of a Swedish
84 population⁶.

85

86 Epigenetic marks in sperm may provide a mechanistic pathway through which offspring
87 disease susceptibility can be altered, a hypothesis supported by studies in rodent models of
88 paternal obesity, diabetes and manipulation of dietary folate⁷⁻⁹. Changes in sperm DNA
89 methylation, histone modifications and small RNA content have also been associated with
90 increased disease susceptibility in offspring of fathers exposed to diet-induced obesity⁹⁻¹³, low-
91 protein diet¹⁴ or stress^{15, 16}. Additionally, the paternal seminal plasma has been shown to
92 influence the female oviduct cytokine expression profile and impact the offspring phenotype¹⁷.

93

94 Cholestatic liver conditions are characterized by an impairment of bile acid efflux from the
95 liver resulting in the accumulation of bile acids in the circulation concomitant with
96 dyslipidemia¹⁸. The most common chronic cholestatic liver diseases affecting men are primary

97 sclerosing cholangitis and primary biliary cholangitis with a prevalence of up to 16.2 per
98 100,000 persons and 40.2 per 100,000 persons respectively in the general population ¹⁹.

99

100 We have previously reported that offspring exposed to maternal cholestasis during gestation
101 are predisposed to developing increased adiposity, abnormal lipid profiles, diabetes and non-
102 alcoholic fatty liver disease²⁰. In addition, a previous study has shown that 4 months of 0.5%
103 CA dietary supplementation to male mice resulted in reduced fertility, concomitant with
104 decreased sperm count and smaller offspring litters. Further analysis showed that after 2
105 months of CA diet, the blood-testis-barrier (BTB) was no longer intact and cell aggregates were
106 visible in the centre of the seminiferous tubules and this was associated with decreased CX43
107 accumulation in gap-junctions²¹.

108

109 In this study, we used a mouse model to establish whether paternal cholestasis influences
110 offspring susceptibility to developing obesity and adiposity-associated cardiometabolic
111 disease. As cholestatic conditions are typically treated with ursodeoxycholic acid (UDCA)¹⁸,
112 we have also explored the effect of paternal cholestasis treatment with UDCA on offspring
113 health.

114

115 **Materials and methods**

116 **Animal experiments**

117 All procedures were approved by the Animal Welfare and Ethical Review Body at King's
118 College London and carried out according to the UK Animals (Scientific Procedures) Act 1986.
119 Male and female C57BL/6 mice aged 6-8 weeks were purchased from Harlan Laboratories,
120 UK. Mice were housed on a 12 h: 12 h light: dark cycle with *ad libitum* access to food and
121 water. Male mice were assigned to either a RM3 normal chow (NC) diet (**n = 6**) or a RM3 diet

122 supplemented with 0.5% of cholic acid (CA) (n = 10) (LBS Serving Biotechnology, UK). Male
123 mice were kept on the assigned diet for 10 weeks and body weight and food intake was
124 measured weekly. Male mice fed a NC or CA diet were mated to NC-fed female mice of
125 established fertility. Female mice used in the experiments had been previously mated and
126 allowed to deliver 1 litter to establish fertility. During the mating period males were
127 permanently kept with females and had access to *ad libitum* NC diet. Mating was confirmed
128 by the presence of a copulatory plug, after which male mice were fasted for 4 h after 9 am and
129 euthanized by CO₂ inhalation. Serum, liver, gonadal white adipose tissue, subcutaneous white
130 adipose tissue and testes were weighed and snap-frozen. Females were allowed to give birth
131 and litters were left undisturbed for 24 h. On day 2, pup number per litter and pup weight were
132 assessed and litters were standardized to 5-6 pups. Offspring body weight was measured
133 weekly thereafter. Pups were kept on a NC diet from 3 to 12 weeks of age, at which point half
134 of the male and female offspring from each litter were challenged with a calorie-rich western
135 diet (WD) (LBS Serving Biotechnology, UK) until 18 weeks of age. The combination of
136 paternal and offspring exposure resulted in 4 experimental offspring groups: NC NC, CA NC,
137 NC WD, and CA WD (first two letters: paternal dietary exposure; second two letters: offspring
138 dietary exposure) (Supplementary Figure 1). At 18 weeks of age, one male offspring (NC NC:
139 n = 6, CA NC: n = 8, NC WD: n = 6, CA WD: n = 8) and one female offspring (NC NC: n = 4,
140 CA NC: n = 8, NC WD n = 5, CA WD = 10) per litter were euthanized by CO₂ inhalation after
141 4 h of fasting from 9 am and tissues harvested as described above. In a second cohort, the
142 paternal feeding experimental protocol was repeated and a group of male mice fed a 0.5%
143 cholic acid + 0.5% ursodeoxycholic acid (CA+UDCA)-supplemented diet (LBS Serving
144 Biotechnology, UK) was included (NC: n = 10, CA: n = 12, CA+UDCA: n = 9). Male offspring
145 were fed a NC diet until 12 weeks of age and then transferred to WD. The 3 offspring groups
146 according to paternal and offspring diet were NC WD, CA WD, CA+UDCA WD

147 (Supplementary Figure 2). Cardiovascular recordings were made in male offspring (25-29
148 weeks) by radiotelemetry (NC: n = 4, CA: n = 3, CA+UDCA: n = 4) (see below).

149

150 Glucose tolerance test (GTT)

151 At 18 weeks of age one male (NC NC: n = 6, CA NC: n= 8, NC WD: n = 6, CA WD: n= 8)
152 and one female offspring (NC NC: n = 4, CA NC: n = 8, NC WD: n= 4, CA WD: n = 8) per
153 litter were fasted for 6 h from 9 am followed by an intraperitoneal injection of 2 g/kg of D-
154 glucose (Sigma-Aldrich, UK). Blood glucose was measured using a glucometer (AccuCheck,
155 UK) before glucose injection and 15, 30, 45, 60 and 120 min following glucose injection. Tail
156 blood samples were collected prior to glucose injection and 30 minutes after glucose injection
157 for serum insulin measurements. Area under the curve (AUC) was calculated from the
158 measurements from each mouse from before the start of GTT until 120 minutes following
159 glucose injection.

160

161 Radiotelemetry

162 Systolic blood pressure, diastolic blood pressure, heart rate and activity were measured in 1
163 male offspring per litter after surgical implantation of probes (Data Sciences International,
164 USA) in the carotid artery (see supplementary information). Measurements are represented
165 over a 24 h period in zeitgeber time where ZT 0 to ZT 12 is lights-on in the animal colony and
166 ZT 12 to ZT 24 (ZT 0) is lights-off. Light and dark cycle averages were calculated based on
167 the hourly averages taken between ZT 0 - ZT 11 and ZT 12 - ZT 24 respectively.

168

169 Insulin measurements

170 Measurements of serum insulin from blood samples taken before the start of GTT and 30
171 minutes after the start of GTT were undertaken using the Mercodia Mouse Insulin ELISA
172 (Mercodia, Sweden) according to the manufacturer's protocol.

173

174 Lipid measurements

175 Lipids were extracted from frozen liver samples using a lysis buffer containing 0.125M
176 potassium phosphate. Serum and lipids were run on a Unicel DxC 800 autoanalyzer (Beckman-
177 Coulter, the Netherlands) for measurements of total cholesterol, LDL-cholesterol, HDL-
178 cholesterol, triglycerides and free fatty acids as previously described²².

179

180 Total RNA extraction and cDNA synthesis

181 Total RNA was extracted from frozen tissue samples using the RNeasy Mini kit (Qiagen, UK)
182 according to manufacturer's instructions. For cDNA synthesis, total RNA was reverse
183 transcribed using SuperScript™ II Reverse Transcriptase (Thermo Fisher Scientific, UK).
184 RNase inhibition was used to prevent RNA digestion.

185

186 Quantitative Real Time-PCR

187 The expression of target genes of interest was assessed using quantitative RT-PCR with a
188 ViiA™ 7 Real Time PCR System (Thermo Fisher Scientific, UK). cDNA was added in
189 duplicate followed by a reaction mix containing 1X of SYBR Green Jumpstart Readymix
190 (Sigma-Aldrich, UK) and 1 µM of forward/reverse primers. The housekeeping gene
191 *Cyclophilin b* was used as an internal reference for cDNA quality and relative quantification of
192 gene expression. The genes assessed included ATP-binding cassette sub-family G member 5
193 and 8 (*Abcg5* and *Abcg8*), Acetyl-CoA carboxylase 1 and 2 (*Acc1* and *Acc2*), bile salt export
194 pump (*Bsep*), cholesterol 7-alpha-monooxygenase (*Cyp7a1*), sterol 12-alpha-hydroxylase

195 (*Cyp8b1*), fatty acid synthase (*Fas*), HMG-CoA reductase (*Hmgcr*), stearoyl-CoA desaturase
196 (*Scd1*), small heterodimer partner (*Shp*), sterol regulatory element-binding protein 1c (Srebp-
197 1c). Primer sequence list is provided in Supplementary Table 1.

198

199 Statistical analysis

200 Data are presented as mean \pm SEM. Statistical analysis was performed using GraphPad Prism
201 7 software (GraphPad Software Inc., USA). Data was checked for normality using the Shapiro-
202 Wilk normality test. Repeated measures of one-way ANOVA followed by a Newman-Keuls
203 *post-hoc* test or two-way ANOVA followed by a Tukey *post-hoc* test were applied for multiple
204 comparisons. For single comparisons unpaired 2-tailed t-test was used. The significance cut-
205 off was $P \leq 0.05$.

206

207 **Results**

208 ***Cholestasis lowers paternal body weight and causes dyslipidemia***

209 We first established the effect of cholestasis induced by 10 weeks of 0.5% CA feeding on the
210 paternal phenotype. CA-fed fathers were lighter than controls over the duration of the feeding
211 period (Figure 1A) and this was not explained by lower daily food intake (Figure 1B). After 10
212 weeks of CA feeding, liver size was increased by 44% in cholestatic males whereas gonadal
213 (gWAT) and subcutaneous white adipose tissue (sWAT) weight decreased by 58% and 18%
214 respectively (Figure 1C). No changes were observed in testis weight (Figure 1C). Time to mate
215 was not different between fathers from NC and CA groups (4.89 ± 1.4 vs 3.33 ± 0.67 days
216 respectively) (Supplementary Figure 3).

217

218 CA feeding caused an aberrant paternal lipid profile, with raised serum total cholesterol and
219 LDL-cholesterol levels (Figure 1D) and increased hepatic cholesterol content (Figure 1E).

220 Serum and hepatic triglycerides and free fatty acids (FFAs) concentrations were not altered by
221 CA feeding (Figure 1D, E).

222

223 Investigation of the hepatic expression of key genes regulating bile acid homeostasis showed a
224 pro-cholestatic profile with increased hepatic expression of the farnesoid x receptor (FXR)
225 target *Shp* and reduced expression of *Cyp8b1* as compared to controls (Figure 1F). Moreover,
226 trends for increased expression of *Bsep* and decreased expression of *Cyp7a1* were observed.

227

228 ***Offspring litter size, birth weight and morphometry***

229 Birthweight and number of pups per litter was not altered by paternal cholestasis (Figure 2A,
230 B).

231

232 Challenge with a WD resulted in an overall increase in male and female offspring body weight,
233 as well as liver, gWAT, sWAT, and brown adipose tissue (BAT) weight in males (Figure 2C,
234 E, F, H). A decrease in food intake in WD-fed males and females as compared to NC-fed
235 offspring was also observed (Figure 2D, G).

236

237 Despite no differences in total body weight or food intake when compared to NC WD controls
238 (Figure 2C, D), 18 week-old WD-fed male offspring of cholestatic fathers (CA WD) showed a
239 29% increase in liver weight and a 26% decrease in sWAT weight (Figure 2E). These changes
240 were not observed when male offspring were maintained on a NC diet.

241

242 Female offspring of cholestatic fathers fed a NC or WD did not show significant changes in
243 body weight when compared to female progeny of control fathers fed a matched diet (Figure
244 2F). However, at 6 weeks of age female offspring of CA fathers (CA NC) had decreased daily

245 food intake, a trend which persisted until 16 weeks of age (Figure 2G). No differences in organ
246 weight were observed between female offspring of cholestatic and control fathers when fed
247 matched diets (Figure 2H).

248
249 Overall, these results suggest that challenge with a calorie-rich diet affects male and female
250 offspring of cholestatic fathers differently with males being more susceptible to changes in
251 organ morphometry.

252
253 ***Paternal cholestasis has distinct effects on glucose homeostatic responses to western diet in***
254 ***male and female offspring***

255 A glucose tolerance test (GTT) was performed at 18 weeks of age, and circulating insulin was
256 measured prior to glucose injection, and 30 min after glucose injection. Male CA WD offspring
257 showed a trend towards higher blood glucose levels compared to matched NC WD offspring
258 during the GTT (Figure 3 A, B). CA WD male offspring also had significantly raised fasting
259 insulin levels compared to NC WD controls (3.9 ± 0.9 vs 2.5 ± 0.2 ng/mL, respectively) (Figure
260 3C). Thirty minutes after the GTT, a trend for increased insulin levels was still observed. No
261 differences were seen in CA NC compared to NC NC offspring.

262
263 In contrast to male offspring, female WD-fed offspring of CA fathers showed improved
264 glucose tolerance compared to NC WD at 30 and 45 minutes of the GTT challenge (Figure
265 3D). Consistent with the GTT results, the AUC was 14% lower in CA WD female offspring
266 compared to NC WD females (Figure 3E). At the measured time-points, serum insulin levels
267 were not different between CA WD and NC WD females (Figure 3F). No differences were
268 observed in female offspring fed a NC diet.

269

270 Overall, male and female offspring of CA fathers showed distinct glucose homeostasis
271 phenotypes. Specifically, male CA WD offspring have increased fasting insulin when exposed
272 to WD whereas female offspring seem to be protected, to some extent, against WD-induced
273 impairments in glucose tolerance.

274

275 ***Paternal cholestasis affects lipid homeostasis in response to western diet differently in male***
276 ***and female offspring***

277 We next investigated the serum and hepatic lipid profiles in the offspring of cholestatic fathers.
278 WD-fed male offspring of cholestatic fathers had 43% higher levels of circulating total
279 cholesterol, including a 62% increase in LDL-cholesterol and a 60% rise in HDL-cholesterol
280 as compared to NC WD (Figure 4A). However, the changes observed were not attributable to
281 an increase in hepatic gene expression of *Hmgcr*, the rate-limiting enzyme for cholesterol
282 synthesis, or the cholesterol exporters from the liver *Abcg5* and *Abcg8* (Figure 4C). In addition
283 to raised circulating cholesterol, CA WD males had a 30% increase in hepatic triglyceride
284 content compared to NC WD controls (Figure 4B). These findings were consistent with an
285 increase in the hepatic expression of enzymes involved in key steps of fatty acid synthesis, i.e.
286 *Fas* and *Scd1* that were raised by 0.9 and 1.2-fold respectively (Figure 4C). Enhanced synthesis
287 and storage of FFAs as triglycerides are likely to contribute to the increased hepatic triglyceride
288 content in CA WD progeny. No changes in serum or hepatic lipids were seen in NC-fed male
289 offspring.

290

291 In female CA WD and CA NC offspring, no changes in serum or hepatic lipid levels were
292 found when compared to controls fed a matched diet (Figure 4D, E). However, a decrease in
293 the hepatic gene expression of *Srebp-1c*, *Scd1*, *Acc1* and *Acc2*, involved in controlling fatty
294 acid biosynthesis, was seen in CA WD females as compared to NC WD controls (Figure 4F).

295

296 Our results demonstrate that while male CA WD progeny have increased lipid accumulation in
297 the liver and circulation, female offspring do not show a worsened lipid metabolic phenotype
298 as a result of WD.

299

300 ***Paternal cholestasis increases the risk of obesity-associated hypertension in male offspring***
301 ***and paternal UDCA treatment prevents rises in blood pressure***

302 Since CA WD male offspring showed several adiposity-associated cardiovascular risk factors,
303 we next interrogated the effects of paternal cholestasis on the cardiovascular phenotype of the
304 obese male offspring.

305

306 The phenotype of fathers fed a CA+UDCA diet was largely similar to that of CA-fed fathers
307 except for higher serum lipids, and a further suppression in the expression of the bile acid
308 synthesis genes *Cyp7a1* and *Cyp8b1* compared to NC controls (Supplementary Figure 4).

309

310 At 25-29 weeks of age, CA WD male offspring displayed a significant increase in systolic
311 blood pressure at ZT 10, ZT 12, ZT 21 and ZT 22 (Figure 5A). Significant elevations of
312 diastolic blood pressure were also registered in CA WD males at ZT 10, ZT 12, and ZT 21
313 compared to NC WD controls (Figure 5B). In contrast, CA+UDCA WD males had blood
314 pressure levels comparable to those observed in NC WD controls. In particular, at ZT 10, ZT
315 21 and ZT 22 systolic blood pressure of CA+UDCA WD males was significantly lower than
316 CA WD counterparts and comparable to NC WD controls (Figure 5A). Diastolic blood pressure
317 was also lower in CA+UDCA WD male offspring than CA WD males at ZT 10, ZT 12, and
318 ZT 21 and did not differ from NC WD controls (Figure 5B). There were no significant

319 differences in heart rate between progeny groups (Figure 5C), although NC WD male offspring
320 were significantly more active than CA WD and CA+UDCA WD males at ZT 14 (Figure 5D).

321

322 Despite the cardiovascular observations, no significant changes were seen in these older mice
323 in body weight, liver weight or lipid profiles in CA WD and CA+UDCA WD males as
324 compared to NC WD controls, although there was a trend for increased liver weight
325 (Supplementary Figure 5).

326

327 These data indicate that paternal cholestasis is linked to increased predisposition of male
328 offspring to developing obesity-associated hypertension, whereas paternal UDCA treatment of
329 cholestasis can protect against hypertension in the offspring.

330

331 **Discussion**

332 This study has shown that paternal cholestasis is linked to increased susceptibility to adiposity-
333 associated metabolic and cardiovascular disease in the male offspring, and that paternal UDCA
334 treatment can prevent the development of obesity-associated hypertension in the male
335 offspring.

336

337 Offspring of cholestatic fathers did not show a disease-prone phenotype compared to controls
338 until challenged with an obesogenic diet, which differentially affected male and female
339 offspring and resulted in contrasting metabolic phenotypes at 18 weeks of age. When fed the
340 same calorie-rich diet, male offspring of cholestatic fathers showed features associated with
341 the initial stages of metabolic disease, including higher fasting insulin levels and enlarged livers
342 with increased hepatic triglyceride content. We also observed an increase in hepatic *Fas* and
343 *Scd1* expression, markers of lipogenesis. Raised insulin levels and enhanced lipogenesis with

344 hepatic triglyceride formation have been previously been associated with the development of
345 non-alcoholic fatty liver disease, where hepatocytes become insulin resistant and fail to repress
346 lipogenesis and triglyceride accumulation in response to high insulin levels^{23,24}. Moreover, CA
347 WD males showed a decrease in sWAT mass concomitant with hepatic TG accumulation that
348 could be due to impaired sWAT expansion, as TGs have been shown to accumulate in the liver
349 and muscle in the absence of functional adipocytes²⁵. Males fed a WD also had higher serum
350 cholesterol levels, but with no apparent increase in hepatic cholesterol biosynthesis or export.
351

352 Given the cardiovascular risk factors observed in the CA WD offspring, we used radiotelemetry
353 to investigate the cardiovascular phenotype of older obese male offspring of cholestatic fathers,
354 after being exposed to a WD for over 13 weeks. The male CA WD offspring showed an
355 elevation of both systolic and diastolic blood pressure. However, in offspring of cholestatic
356 fathers treated with UDCA, systolic and diastolic blood pressure levels were comparable to NC
357 WD controls. These data show that treatment of cholestatic fathers with UDCA was effective
358 in preventing the development of obesity-associated hypertension in male offspring beyond the
359 levels registered in control NC WD offspring. No increase in heart rate was observed in male
360 CA WD and CA+UDCA WD offspring compared to controls, suggesting that the baroreceptor
361 reflex remained sensitive to raises in blood pressure.

362
363 The mechanisms underlying the increased adiposity-associated cardiometabolic disease
364 susceptibility observed in the male offspring of cholestatic fathers and the protective effect
365 given by paternal UDCA treatment against diet-induced hypertension are unknown but may
366 involve persistent alterations in the paternal sperm epigenome, as observed in previous studies⁷⁻
367 ^{10, 12, 15, 16, 26, 27}. Future studies will address potential changes in the sperm epigenome of
368 cholestatic fathers and cholestatic fathers treated with UDCA that may affect the embryonic

369 developmental trajectory and alter the phenotype of the adult offspring. In addition,
370 investigation of the effects of paternal UDCA administration alone will be pursued to elucidate
371 the protective effect of UDCA treatment of paternal cholestasis against obesity-associated
372 hypertension in the offspring.

373

374 In contrast to male offspring, CA WD female offspring showed improved glucose tolerance
375 compared to matched controls, in parallel with a decrease in the hepatic expression of the
376 lipogenic genes *Srebp-1c*, *Scd1*, *Acc1* and *Acc2*. Overall, these data suggest that protective
377 mechanisms may be in place in female offspring of cholestatic fathers to counteract the
378 negative effects of exposure to WD feeding. Discrepancies between male and female offspring
379 phenotypes have previously been reported in rodent models of paternal exposure to low-protein
380 diet and obesity^{10, 11, 28}. However, the mechanisms underlying the sexual dimorphism found in
381 these models have not been described. Sex-specific effects have also been observed in models
382 of fetal exposure to an adverse intrauterine environment. For example, in a rodent model of
383 placental insufficiency, sex-specific effects on the cardiovascular phenotype of the offspring
384 have been linked to reproductive hormones including estrogen and testosterone²⁹. Moreover,
385 sex chromosomes and genomic imprinted regions may play a role in influencing the
386 developmental trajectory of the offspring. For example, in murine embryonic stem cells, sex
387 chromosome complement alone has been associated with DNA methylome-wide differences³⁰
388 and with differential autosomal expression of coding and non-coding RNA³¹. In addition,
389 differential expression of imprinted loci has been observed in male and female murine
390 embryonic stem cells, despite maintaining correct parental imprinting patterns³¹ and studies
391 performed on the liver of adult mice have shown sex-dependent genome imprinting effects that
392 were correlated to complex traits such as body and liver weight³². A further study has identified
393 1184 differentially methylated CpG sites between men and women, enriched at imprinted genes

394 and distributed across all autosomes³³. It is thus possible that changes to the paternal
395 epigenome may interact with different factors present in the early embryo and later in life,
396 including the sex chromosomes, genomic imprinted regions and reproductive hormones, to
397 differently modulate the embryonic developmental trajectory and adult metabolic phenotype
398 of male and female offspring from cholestatic fathers.

399

400 A limitation of the study is that during the mating period the paternal CA diet was discontinued
401 and thus circulating BA levels would have gradually decreased in the CA group over the mating
402 period. This would explain less marked changes in hepatic *Cyp7a1* and *Bsep* expression than
403 would be anticipated. It was necessary to discontinue the paternal CA diet during the mating
404 period to avoid exposing females to CA, which has previously been shown to influence the
405 offspring phenotype later in life²⁰. However, mean time to mate was approximately 3 days in
406 the CA group and fathers would still have a significant derangement in BA and lipid levels
407 caused by 10 weeks of CA feeding at the time of mating. Another possible caveat of the study
408 is that implantation of the radiotelemetry probe has previously been shown to result in weight
409 loss in mice for up to 15 days³⁴ and may have influenced the metabolic phenotype of the male
410 offspring.

411

412 It is also important to note that CA feeding of fathers resulted in a lower paternal body weight
413 despite causing hepatomegaly and dyslipidemia. Previous models of bile acid feeding have
414 reported similar findings with liver enlargement secondary to increased hepatocyte size,
415 dilation of interlobular bile ducts, parenchymal mitosis and inflammation in the liver^{35, 36}.
416 Dyslipidemia is also a feature of cholestasis since repression of *Cyp7a1* expression, an enzyme
417 which catalyzes bile acid synthesis from cholesterol, results in hepatic cholesterol
418 accumulation³⁷. The observation that CA-fed fathers had smaller white adipose depots (gWAT

419 and sWAT) was consistent with the decreased body weight in fathers throughout the CA
420 feeding period. Rather than losing weight, CA-fed fathers appeared unable to gain weight at
421 the same rate as controls, findings which align with a previous report of lower body weight in
422 mice exposed to CA feeding for 102 days³⁸.

423

424 In conclusion, paternal cholestasis is associated with sex-specific effects on offspring
425 susceptibility to metabolic disease and male progeny present a more disease-prone phenotype
426 with features of metabolic disease and hypertension when exposed to an obesogenic diet.
427 Paternal UDCA treatment has a protective effect against the exacerbation of obesity-associated
428 hypertension in male offspring. The most prevalent cholestatic diseases in humans are primary
429 sclerosing cholangitis and primary biliary cholangitis and UDCA is a common treatment for
430 these conditions¹⁸. The results presented in this study warrant investigations into the metabolic
431 and cardiovascular phenotype of children of fathers with primary sclerosing cholangitis and
432 primary biliary cholangitis, who may be taking UDCA at the time of conception of their child.

433

434 **Acknowledgements**

435 We would like to thank Mr Piet Beekhof from Dr Eugene Jansen's lab for the help and support
436 with the serum and hepatic lipid measurements, and Shahina Begum for the statistical advice.

437

438 **Conflict of interest:**

439 The authors have no conflict of interest to disclose.

440

441 **References**

- 442 1. Beaglehole R, Bonita R, Horton R, Adams C, Alleyne G, Asaria P *et al*. Priority actions
443 for the non-communicable disease crisis. *Lancet* 2011; **377**(9775): 1438-47.

444

445 2. Leggio M, Lombardi M, Caldarone E, Severi P, D'Emidio S, Armeni M *et al.* The
446 relationship between obesity and hypertension: an updated comprehensive overview on
447 vicious twins. *Hypertens. Res.* 2017.

448

449 3. Hur SS, Cropley JE, Suter CM. Paternal epigenetic programming: evolving metabolic
450 disease risk. *J. Mol. Endocrinol.* 2017; **58**(3): R159-R168.

451

452 4. Figueroa-Colon R, Arani RB, Goran MI, Weinsier RL. Paternal body fat is a
453 longitudinal predictor of changes in body fat in premenarcheal girls. *Am. J. Clin. Nutr.*
454 2000; **71**(3): 829-34.

455

456 5. Loomba R, Hwang SJ, O'Donnell CJ, Ellison RC, Vasani RS, D'Agostino RB, Sr. *et al.*
457 Parental obesity and offspring serum alanine and aspartate aminotransferase levels: the
458 Framingham heart study. *Gastroenterology* 2008; **134**(4): 953-9.

459

460 6. Kaati G, Bygren LO, Edvinsson S. Cardiovascular and diabetes mortality determined
461 by nutrition during parents' and grandparents' slow growth period. *Eur. J. Hum. Genet.*
462 2002; **10**(11): 682-8.

463

464 7. Lambrot R, Xu C, Saint-Phar S, Chountalos G, Cohen T, Paquet M *et al.* Low paternal
465 dietary folate alters the mouse sperm epigenome and is associated with negative
466 pregnancy outcomes. *Nature communications* 2013; **4**: 2889.

467

- 468 8. Wei Y, Yang CR, Wei YP, Zhao ZA, Hou Y, Schatten H *et al.* Paternally induced
469 transgenerational inheritance of susceptibility to diabetes in mammals. *Proc. Natl.*
470 *Acad. Sci. U. S. A.* 2014; **111**(5): 1873-8.
- 471
- 472 9. de Castro Barbosa T, Ingerslev LR, Alm PS, Versteyhe S, Massart J, Rasmussen M *et*
473 *al.* High-fat diet reprograms the epigenome of rat spermatozoa and transgenerationally
474 affects metabolism of the offspring. *Molecular metabolism* 2016; **5**(3): 184-97.
- 475
- 476 10. Ng SF, Lin RC, Laybutt DR, Barres R, Owens JA, Morris MJ. Chronic high-fat diet in
477 fathers programs beta-cell dysfunction in female rat offspring. *Nature* 2010; **467**(7318):
478 963-6.
- 479
- 480 11. Fullston T, Ohlsson Teague EM, Palmer NO, DeBlasio MJ, Mitchell M, Corbett M *et*
481 *al.* Paternal obesity initiates metabolic disturbances in two generations of mice with
482 incomplete penetrance to the F2 generation and alters the transcriptional profile of testis
483 and sperm microRNA content. *FASEB J.* 2013; **27**(10): 4226-43.
- 484
- 485 12. Grandjean V, Fourre S, De Abreu DA, Derieppe MA, Remy JJ, Rassoulzadegan M.
486 RNA-mediated paternal heredity of diet-induced obesity and metabolic disorders. *Sci.*
487 *Rep.* 2015; **5**: 18193.
- 488
- 489 13. Chen Q, Yan M, Cao Z, Li X, Zhang Y, Shi J *et al.* Sperm tsRNAs contribute to
490 intergenerational inheritance of an acquired metabolic disorder. *Science* 2016;
491 **351**(6271): 397-400.
- 492

- 493 14. Carone BR, Fauquier L, Habib N, Shea JM, Hart CE, Li R *et al.* Paternally induced
494 transgenerational environmental reprogramming of metabolic gene expression in
495 mammals. *Cell* 2010; **143**(7): 1084-96.
496
- 497 15. Rodgers AB, Morgan CP, Bronson SL, Revello S, Bale TL. Paternal stress exposure
498 alters sperm microRNA content and reprograms offspring HPA stress axis regulation.
499 *J. Neurosci.* 2013; **33**(21): 9003-12.
500
- 501 16. Rodgers AB, Morgan CP, Leu NA, Bale TL. Transgenerational epigenetic
502 programming via sperm microRNA recapitulates effects of paternal stress. *Proc. Natl.*
503 *Acad. Sci. U. S. A.* 2015; **112**(44): 13699-704.
504
- 505 17. Bromfield JJ, Schjenken JE, Chin PY, Care AS, Jasper MJ, Robertson SA. Maternal
506 tract factors contribute to paternal seminal fluid impact on metabolic phenotype in
507 offspring. *Proc. Natl. Acad. Sci. U. S. A.* 2014; **111**(6): 2200-5.
508
- 509 18. Poupon R, Chazouilleres O, Poupon RE. Chronic cholestatic diseases. *J. Hepatol.* 2000;
510 **32**(1 Suppl): 129-40.
511
- 512 19. Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis
513 and primary biliary cirrhosis: a systematic review. *J. Hepatol.* 2012; **56**(5): 1181-8.
514
- 515 20. Papacleovoulou G, Abu-Hayyeh S, Nikolopoulou E, Briz O, Owen BM, Nikolova V *et*
516 *al.* Maternal cholestasis during pregnancy programs metabolic disease in offspring. *J.*
517 *Clin. Invest.* 2013; **123**(7): 3172-81.

518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542

21. Baptissart M, Vega A, Martinot E, Pommier AJ, Houten SM, Marceau G *et al.* Bile acids alter male fertility through G-protein-coupled bile acid receptor 1 signaling pathways in mice. *Hepatology* 2014; **60**(3): 1054-65.
22. Nikolova V, Papacleovoulou G, Bellafante E, Borges Manna L, Jansen E, Baron S *et al.* Changes in LXR signaling influence early-pregnancy lipogenesis and protect against dysregulated fetoplacental lipid homeostasis. *Am. J. Physiol. Endocrinol. Metab.* 2017: ajpendo.00449.2016.
23. Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. *Gastroenterology* 2014; **146**(3): 726-35.
24. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. *J. Clin. Invest.* 2005; **115**(5): 1343-51.
25. Pajvani UB, Trujillo ME, Combs TP, Iyengar P, Jelicks L, Roth KA *et al.* Fat apoptosis through targeted activation of caspase 8: a new mouse model of inducible and reversible lipoatrophy. *Nat. Med.* 2005; **11**(7): 797-803.
26. Radford EJ, Ito M, Shi H, Corish JA, Yamazawa K, Isganaitis E *et al.* In utero effects. In utero undernourishment perturbs the adult sperm methylome and intergenerational metabolism. *Science* 2014; **345**(6198): 1255903.

543

544 27. Cropley JE, Eaton SA, Aiken A, Young PE, Giannoulatou E, Ho JW *et al.* Male-lineage
545 transmission of an acquired metabolic phenotype induced by grand-paternal obesity.
546 *Molecular metabolism* 2016; **5**(8): 699-708.

547

548 28. Watkins AJ, Sinclair KD. Paternal low protein diet affects adult offspring
549 cardiovascular and metabolic function in mice. *Am. J. Physiol. Heart Circ. Physiol.*
550 2014; **306**(10): H1444-52.

551

552 29. Ojeda NB, Grigore D, Yanes LL, Iliescu R, Robertson EB, Zhang H *et al.* Testosterone
553 contributes to marked elevations in mean arterial pressure in adult male intrauterine
554 growth restricted offspring. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 2007; **292**(2):
555 R758-63.

556

557 30. Habibi E, Brinkman Arie B, Arand J, Kroeze Leonie I, Kerstens Hindrik HD, Matarese
558 F *et al.* Whole-Genome Bisulfite Sequencing of Two Distinct Interconvertible DNA
559 Methylomes of Mouse Embryonic Stem Cells. *Cell Stem Cell* 2013; **13**(3): 360-369.

560

561 31. Werner RJ, Schultz BM, Huhn JM, Jelinek J, Madzo J, Engel N. Sex chromosomes
562 drive gene expression and regulatory dimorphisms in mouse embryonic stem cells.
563 *Biol. Sex Differ.* 2017; **8**(1): 28.

564

565 32. Hager R, Cheverud JM, Leamy LJ, Wolf JB. Sex dependent imprinting effects on
566 complex traits in mice. *BMC Evol. Biol.* 2008; **8**: 303.

567

- 568 33. Singmann P, Shem-Tov D, Wahl S, Grallert H, Fiorito G, Shin SY *et al.*
569 Characterization of whole-genome autosomal differences of DNA methylation between
570 men and women. *Epigenetics & chromatin* 2015; **8**: 43.
571
- 572 34. Mills PA, Huetteman DA, Brockway BP, Zwiers LM, Gelsema AJ, Schwartz RS *et al.*
573 A new method for measurement of blood pressure, heart rate, and activity in the mouse
574 by radiotelemetry. *J. Appl. Physiol.* 2000; **88**(5): 1537-44.
575
- 576 35. Bodewes F, Bijvelds MJ, de Vries W, Baller JFW, Gouw ASH, de Jonge HR *et al.*
577 Cholic Acid Induces a Cftr Dependent Biliary Secretion and Liver Growth Response in
578 Mice. *PLoS One* 2015; **10**(2).
579
- 580 36. Fickert P, Zollner G, Fuchsbichler A, Stumtner C, Pojer C, Zenz R *et al.* Effects of
581 ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in
582 mouse liver. *Gastroenterology* 2001; **121**(1): 170-83.
583
- 584 37. Murphy C, Parini P, Wang J, Bjorkhem I, Eggertsen G, Gafvels M. Cholic acid as key
585 regulator of cholesterol synthesis, intestinal absorption and hepatic storage in mice.
586 *Biochim. Biophys. Acta* 2005; **1735**(3): 167-75.
587
- 588 38. Wang R, Lam P, Liu L, Forrest D, Yousef IM, Mignault D *et al.* Severe cholestasis
589 induced by cholic acid feeding in knockout mice of sister of P-glycoprotein. *Hepatology*
590 2003; **38**(6): 1489-99.
591
592

593 **Figure legends**

594 Figure 1 - Paternal morphometry and metabolic profile. (A) Paternal body weight during
595 feeding period. **n = 6 - 10**. (B) Paternal daily food intake during feeding period. **n = 6 - 10**. (C)
596 Paternal organ weight. **n = 6 - 10**. (D) Paternal serum lipid levels. n = 6. (E) Paternal hepatic
597 lipid levels. n = 6 (F) Paternal hepatic expression of bile acid homeostasis genes. n = 6. Data
598 are presented as mean \pm SEM. * $P \leq 0.05$. Unpaired 2-tailed t-test was used.

599

600 Figure 2 - Offspring birth parameters and morphometry later in life. (A) Offspring birth weight.
601 n = 6 - 10. (B) Offspring pup number per litter. n = 6 - 10. (C) Male offspring body weight
602 from 1 to 18 weeks of age. n = 6 - 10. (D) Male offspring mean average daily food intake from
603 4 to 17 weeks of age. n = 6 - 10. (E) Male offspring organ weight. n = 6 - 8. (F) Female
604 offspring body weight from 1 to 18 weeks of age. n = 4 - 10. (G) Female offspring mean daily
605 food intake from 4 to 17 weeks of age. n = 4 - 10. (H) Female offspring organ weight. n = 4 -
606 10. Data are presented as mean \pm SEM. * $P \leq 0.05$ for effects due to WD challenge in
607 comparisons vs NC NC and CA NC; # $P \leq 0.05$ for effects due to paternal cholestasis in
608 comparisons of NC NC vs CA NC or NC WD vs CA WD. Repeated measures of one-way
609 ANOVA followed by a Newman-Keuls *post-hoc* test was used.

610

611 Figure 3 - Glucose homeostasis in offspring. (A, B) Glucose tolerance test (GTT) and area
612 under the curve (AUC) in male offspring. n = 6 - 8. (C) Measurement of insulin levels in male
613 offspring prior to and 30 minutes after glucose injection. n = 6 - 8. (D, E) Glucose tolerance
614 test (GTT) and area under the curve (AUC) in female offspring. n = 4 - 8. (F) Measurement of
615 insulin levels in female offspring prior to and 30 minutes after glucose injection. n = 4 - 8.
616 Data are presented as mean \pm SEM. * $P \leq 0.05$ for effects due to WD challenge in comparisons
617 vs NC NC and CA NC; & $P \leq 0.05$ for effects due to WD challenge in comparisons vs NC NC;

618 \$ $P \leq 0.05$ for effects due to WD challenge in comparisons vs CA WD; # $P \leq 0.05$ for effects
619 due to paternal cholestasis in comparisons vs NC WD. Repeated measures of two-way
620 ANOVA followed by a Tukey *post-hoc* test was used on GTT data comparisons, repeated
621 measures of one-way ANOVA followed by a Newman-Keuls *post-hoc* test was used on AUC
622 and insulin measurements data.

623

624 Figure 4 - Serum and hepatic lipid profiles in offspring. (A) Serum lipid levels in male
625 offspring. n = 6. (B) Hepatic lipid levels in male offspring. n = 6. (C) Hepatic expression of
626 lipid homeostasis genes in male offspring. n = 6. (D) Serum lipid levels in female offspring. n
627 = 4 – 6. (E) Hepatic lipid levels in female offspring. n = 4 – 6. (F) Hepatic expression of lipid
628 homeostasis genes in female offspring. n = 4 – 6. Data are presented as mean \pm SEM. * $P \leq$
629 0.05 for effects due to WD challenge in comparisons vs NC NC and CA NC; # $P \leq 0.05$ for
630 effects due to paternal cholestasis in comparisons vs NC WD. Repeated measures of one-way
631 ANOVA followed by a Newman-Keuls *post-hoc* test was used.

632

633 Figure 5 - Effect of paternal cholestasis and ursodeoxycholic acid (UDCA) treatment of
634 paternal cholestasis on cardiovascular parameters in the offspring. (A) Male offspring systolic
635 blood pressure over a 24 h period and mean systolic blood pressure during the light and dark
636 cycles. (B) Male offspring diastolic blood pressure over a 24 h period and mean diastolic blood
637 pressure during the light and dark cycles. (C) Male offspring heart rate over a 24 h period and
638 mean heart rate during the light and dark cycles (D) Male offspring activity over a 24 h period
639 and mean activity during the light and dark cycles. Data are presented as mean \pm SEM. n = 3 –
640 4. # $P \leq 0.05$ for effects due to paternal cholestasis in comparisons vs NC WD; † $P \leq 0.05$ for
641 effects due to untreated paternal cholestasis in comparisons vs CA+UDCA WD; ‡ for effects
642 due to paternal UDCA treatment in comparisons vs CA WD. Repeated measures of two-way

643 ANOVA followed by a Tukey *post-hoc* test was used on 24 h recordings data comparisons,
644 repeated measures of one-way ANOVA followed by a Newman-Keuls *post-hoc* test was used
645 on mean light and dark cycle comparisons.

646